Selective inhibition of BET bromodomains P Filippakopoulos, J Qi, S Picaud, Y Shen, WB Smith, O Fedorov, ... Nature 468 (7327), 1067-1073, 2010 | 4433 | 2010 |
BET bromodomain inhibition as a therapeutic strategy to target c-Myc JE Delmore, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, ... Cell 146 (6), 904-917, 2011 | 3196 | 2011 |
Selective inhibition of tumor oncogenes by disruption of super-enhancers J Lovén, HA Hoke, CY Lin, A Lau, DA Orlando, CR Vakoc, JE Bradner, ... Cell 153 (2), 320-334, 2013 | 2928 | 2013 |
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia J Zuber, J Shi, E Wang, AR Rappaport, H Herrmann, EA Sison, D Magoon, ... Nature 478 (7370), 524-528, 2011 | 2153 | 2011 |
HDAC2 negatively regulates memory formation and synaptic plasticity JS Guan, SJ Haggarty, E Giacometti, JH Dannenberg, N Joseph, J Gao, ... Nature 459 (7243), 55-60, 2009 | 1810 | 2009 |
Transcriptional amplification in tumor cells with elevated c-Myc CY Lin, J Lovén, PB Rahl, RM Paranal, CB Burge, JE Bradner, TI Lee, ... Cell 151 (1), 56-67, 2012 | 1684 | 2012 |
Phthalimide conjugation as a strategy for in vivo target protein degradation GE Winter, DL Buckley, J Paulk, JM Roberts, A Souza, S Dhe-Paganon, ... Science 348 (6241), 1376-1381, 2015 | 1620 | 2015 |
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins G Lu, RE Middleton, H Sun, MV Naniong, CJ Ott, CS Mitsiades, KK Wong, ... Science 343 (6168), 305-309, 2014 | 1570 | 2014 |
Transcriptional addiction in cancer JE Bradner, D Hnisz, RA Young Cell 168 (4), 629-643, 2017 | 1139 | 2017 |
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies JM Stommel, AC Kimmelman, H Ying, R Nabioullin, AH Ponugoti, ... Science 318 (5848), 287-290, 2007 | 1122 | 2007 |
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase … P Bali, M Pranpat, J Bradner, M Balasis, W Fiskus, F Guo, K Rocha, ... Journal of Biological Chemistry 280 (29), 26729-26734, 2005 | 967 | 2005 |
R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling R Su, L Dong, C Li, S Nachtergaele, M Wunderlich, Y Qing, X Deng, ... Cell 172 (1), 90-105. e23, 2018 | 952 | 2018 |
Direct inhibition of the NOTCH transcription factor complex RE Moellering, M Cornejo, TN Davis, CD Bianco, JC Aster, SC Blacklow, ... Nature 462 (7270), 182-188, 2009 | 936 | 2009 |
YY1 is a structural regulator of enhancer-promoter loops AS Weintraub, CH Li, AV Zamudio, AA Sigova, NM Hannett, DS Day, ... Cell 171 (7), 1573-1588. e28, 2017 | 929 | 2017 |
Chemical phylogenetics of histone deacetylases JE Bradner, N West, ML Grachan, EF Greenberg, SJ Haggarty, T Warnow, ... Nature chemical biology 6 (3), 238-243, 2010 | 853 | 2010 |
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma B Chapuy, MR McKeown, CY Lin, S Monti, MGM Roemer, J Qi, PB Rahl, ... Cancer cell 24 (6), 777-790, 2013 | 849 | 2013 |
The dTAG system for immediate and target-specific protein degradation B Nabet, JM Roberts, DL Buckley, J Paulk, S Dastjerdi, A Yang, ... Nature chemical biology 14 (5), 431-441, 2018 | 845 | 2018 |
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ... Cancer research 67 (24), 11924-11932, 2007 | 843 | 2007 |
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma T Hideshima, JE Bradner, J Wong, D Chauhan, P Richardson, ... Proceedings of the National Academy of Sciences 102 (24), 8567-8572, 2005 | 761 | 2005 |
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia S Gröschel, MA Sanders, R Hoogenboezem, E de Wit, BAM Bouwman, ... Cell 157 (2), 369-381, 2014 | 738 | 2014 |